Venaxis
Venaxis is a Colorado-based in vitro diagnostic company focused on developing and commercializing its unique multi-biomarker diagnostic
Business Model:
Revenue: $0
Employees: 11-50
Rankings
Industries / Tags:
Detailed Venaxis Information
Geographic Data
Address:
City: Castle Rock
State: Colorado
Zip:
Country: United States
Financial Info
Stage:
post ipo equity
Raised Last:
$18M
Raised Total:$18M
Social
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Venaxis is a Colorado-based in vitro diagnostic company focused on developing and commercializing its unique multi-biomarker diagnostic test, the APPY1 Test. Designed to aid in the identification of patients at low risk for acute appendicitis, the APPY1 Test is a simple, rapid blood test that may help physicians manage the large number of children and adolescents who enter hospital emergency departments with abdominal pain, suspected of acute appendicitis. Determining whether a patient requires emergency surgery for appendicitis is critical and current practices have important limitations.
Contact Phone:
Contact Email:
Venaxis went public on 1/27/2003 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
1/27/2003
Ticker Symbol:
APPY
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 4/2014 | Post-IPO Equity | $18.4M |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 9/2016 | Riot Blockchain |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
